

SAS/AC:kam 03/17/04 262820  
PATENT

Attorney Reference Number 4239-58378  
Application Number 09/807,148

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: *Tosato et al.*

Application No. 09/807,148

Filed: April 5, 2001

Confirmation No. 2215

For: USE OF CALRETICULIN AND  
CALRETICULIN FRAGMENTS TO  
INHIBIT ENDOTHELIAL CELL  
GROWTH AND ANGIOGENESIS, AND  
SUPPRESS TUMOR GROWTH

Examiner: Misook Yu, Ph.D.

Art Unit: 1642

Attorney Reference No. 4239-58378

MAIL STOP NON-FEE AMENDMENT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

## CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP NON-FEE AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed

FREE VALUE ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
02	4550
FEE CODE	VALUE PLANNED
1814	110

RECEIVED  
AUG 16 2004  
TECH CENTER 1600/2900

## TERMINAL DISCLAIMER

The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, The National Institutes of Health, ("THE GOVERNMENT") is the owner of the entire interest in the above-identified application. An assignment was submitted to the United States Patent and Trademark Office on March 17, 2004. A copy of this assignment is attached hereto.

THE GOVERNMENT hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of United States Patent No. 6,596,690, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent No. 6,596,690, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

THE GOVERNMENT does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent No. 6,596,690, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

I am empowered to act on behalf of THE GOVERNMENT.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were

Page 1 of 2

4/2004 GDUCKETT 00000004 024550 09807148  
Ref: 00000004 DAK: 024550 09807148  
C:1814 110.00 DA

SAS/AC:kam 03/17/04 262820  
PATENT

Attorney Reference Number 4239-58378  
Application Number 09/807,148

made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

THE GOVERNMENT

03/18/04  
Date

Myddel Baker  
Name: Myddel Baker 54,398  
Title: Technology Licensing Specialist